The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | A Phase II trial of busulfan, fludarabine, cladribine, thiotepa, and venetoclax conditioning for AML
Uday Popat, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses findings from a Phase II trial (NCT04708054) of myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa, and venetoclax conditioning for high-risk acute myeloid leukemia (AML). Prof. Popat highlights that the regimen demonstrated a three-year progression-free survival of 58% and a relapse rate of 24%, with particularly encouraging results in TP53-negative patients. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
